{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:35:28Z","timestamp":1761863728547,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.drugalcdep.2017.06.033","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T14:01:44Z","timestamp":1501077704000},"page":"362-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Abuse liability of intravenous buprenorphine vs. buprenorphine\/naloxone: Importance of absolute naloxone amount"],"prefix":"10.1016","volume":"179","author":[{"given":"Jermaine D.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne M.","family":"Manubay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Mogali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena E.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Madera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suky","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudassir","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0005","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1002\/hep.1840360712","article-title":"Prevention of spread of hepatitis C","volume":"36","author":"Alter","year":"2002","journal-title":"Hepatolology"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0010","first-page":"95","article-title":"Abuse liability of buprenorphine-a study among experienced drug users","volume":"42","author":"Bedi","year":"1998","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/00952990802585406","article-title":"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine\/naloxone to the Malaysian market","volume":"35","author":"Bruce","year":"2009","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0020","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1086\/508184","article-title":"Buprenorphine use: the international experience","volume":"43","author":"Carrieri","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.102.038141","article-title":"Self-administration of intravenous buprenorphine and the buprenorphine\/naloxone combination by recently detoxified heroin abusers","volume":"303","author":"Comer","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0030","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1124\/jpet.105.090423","article-title":"Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals","volume":"315","author":"Comer","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0035","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.npp.1301479","article-title":"Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers","volume":"33","author":"Comer","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0040","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"year":"2012","series-title":"Understanding the New Statistics: Effect Sizes, Confidence Intervals, and Meta-Analysis","author":"Cumming","key":"10.1016\/j.drugalcdep.2017.06.033_bib0045"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0956797613504966","article-title":"The new statistics: why and how","volume":"25","author":"Cumming","year":"2014","journal-title":"Psychol. Sci."},{"year":"2013","series-title":"Heroin Domestic Monitor Program","author":"Drug Enforcement Administration","key":"10.1016\/j.drugalcdep.2017.06.033_bib0055"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0060","series-title":"Emergency Medicine: A Comprehensive Study Guide","first-page":"1071","article-title":"Opioids","author":"Doyon","year":"2004"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0065","first-page":"1","article-title":"Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine\/naloxone tablet formulation in healthy volunteers","volume":"41","author":"Fischer","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(98)00008-8","article-title":"Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts","volume":"50","author":"Fudala","year":"1998","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0075","first-page":"191","article-title":"Superanova accessible general linear modeling","volume":"63","author":"Gagnon","year":"1990","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0080","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0085","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0090","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FBP.0b013e3283641c3d","article-title":"A review of human drug self-administration procedures","volume":"24","author":"Jones","year":"2013","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0095","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/adb.12163","article-title":"Abuse potential of intranasal buprenorphine versus buprenorphine\/naloxone in buprenorphine-maintained heroin users","volume":"20","author":"Jones","year":"2015","journal-title":"Addict. Biol."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0100","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0022-3565(25)20504-3","article-title":"The reinforcing and subjective effects of morphine in post-addicts: a dose-response study","volume":"259","author":"Lamb","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.drugalcdep.2011.04.002","article-title":"Post-marketing surveillance of buprenorphine-naloxone in Australia Diversion, injection and adherence with supervised dosing","volume":"118","author":"Larance","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2013.12.005","article-title":"The diversion and injection of a buprenorphine-naloxone soluble film formulation","volume":"136","author":"Larance","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0115","first-page":"919","article-title":"Tackling subutex abuse in Singapore","volume":"47","author":"Lee","year":"2006","journal-title":"Singapore Med. J."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0120","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"16","author":"Mattick","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1521-0391.2009.00008.x","article-title":"Indicators of buprenorphine and methadone use and abuse: what do we know?","volume":"19","author":"Maxwell","year":"2010","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0009-9236(96)90173-3","article-title":"Buprenorphine and naloxone interactions in opiate-dependent volunteers","volume":"60","author":"Mendelson","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002130050804","article-title":"Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized: opiate-dependent volunteers","volume":"141","author":"Mendelson","year":"1999","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0140","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1360-0443.2011.03424.x","article-title":"The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine\/naloxone tablets in opioid abusers","volume":"106","author":"Middleton","year":"2011","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.drugalcdep.2017.06.033_bib0145","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/BF00212842","article-title":"Buprenorphine and naloxone alone and in combination in opioid-dependent humans","volume":"94","author":"Preston","year":"1988","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0376-8716(90)90136-3","article-title":"Effects of sublingually given naloxone in opioid-dependent human volunteers","volume":"25","author":"Preston","year":"1990","journal-title":"Drug Alcohol Depend."},{"year":"2009","series-title":"SPSS 18.0.0 for Windows","author":"SPSS I","key":"10.1016\/j.drugalcdep.2017.06.033_bib0155"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0160","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0165","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s002130050199","article-title":"The effects of buprenorphine in buprenorphine-maintained volunteers","volume":"129","author":"Strain","year":"1997","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0170","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1086\/432888","article-title":"Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence","volume":"41","author":"Sullivan","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","article-title":"Effects of high-dose intravenous buprenorphine in experienced opioid abusers","volume":"24","author":"Umbricht","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0180","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugalcdep.2010.03.014","article-title":"Injection of buprenorphine and buprenorphine\/naloxone tablets in Malaysia","volume":"111","author":"Vicknasingam","year":"2010","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0185","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0190","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0195","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","article-title":"Acute administration of buprenorphine in humans: partial agonist and blockage effect","volume":"274","author":"Walsh","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.drugalcdep.2017.06.033_bib0205","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0022-3565(24)36921-6","article-title":"Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers","volume":"282","author":"Zacny","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617303678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617303678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:00:20Z","timestamp":1759827620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617303678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":41,"alternative-id":["S0376871617303678"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.06.033","relation":{},"ISSN":["0376-8716"],"issn-type":[{"type":"print","value":"0376-8716"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abuse liability of intravenous buprenorphine vs. buprenorphine\/naloxone: Importance of absolute naloxone amount","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}